Zacks Investment Research on MSN1d
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring ...
Zacks Investment Research on MSN15d
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down
Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per share of ...
The Victoria Advocate17d
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...
ETF Daily News15d
Nevro Corp. (NYSE:NVRO) Receives $6.43 Consensus Target Price from Brokerages
Nevro Corp. (NYSE:NVRO – Get Free Report ... The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence ...
Yahoo Finance15d
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down
a responsive and personalized pain management platform that powers the HFX iQ spinal cord stimulation (SCS) system. In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system ...